Galecto Inc.

5.97+0.0100+0.17%Vol 3411Y Perf -60.27%
Apr 23rd, 2021 09:48 DELAYED
BID5.90 ASK6.00
Open5.97 Previous Close5.85
Pre-Market- After-Market-
 - -%  - -
Target Price
18.50 
Analyst Rating
— — 0.00
Potential %
210.40 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap150.81M 
Earnings Rating
Price Range Ratio 52W %
3.14 
Earnings Date
2nd Apr 2021

Today's Price Range

5.975.97

52W Range

5.5817.99

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
0.68%
1 Month
-15.22%
3 Months
-51.43%
6 Months
-
1 Year
-60.27%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GLTO5.970.01000.17
AAPL133.311.37001.04
GOOG2 283.0615.14000.67
MSFT258.431.26000.49
XOM55.470.20000.36
WFC43.280.58001.36
JNJ164.95-0.2300-0.14
FB298.061.54000.52
GE13.530.12000.89
JPM148.080.71000.48
Earnings HistoryEstimateReportedSurprise %
Q03 2020--55.25-
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume341
Shares Outstanding25.26M
Trades Count4
Dollar Volume337.92K
Avg. Volume33.79K
Avg. Weekly Volume57.12K
Avg. Monthly Volume54.51K
Avg. Quarterly Volume36.64K

Galecto Inc. (NYSE: GLTO) stock closed at 5.96 per share at the end of the most recent trading day (a 1.88% change compared to the prior day closing price) with a volume of 34.91K shares and market capitalization of 150.81M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 20 people. Galecto Inc. CEO is Hans T. Schambye.

The one-year performance of Galecto Inc. stock is -60.27%, while year-to-date (YTD) performance is -52.36%. GLTO stock has a five-year performance of %. Its 52-week range is between 5.58 and 17.99, which gives GLTO stock a 52-week price range ratio of 3.14%

Galecto Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 0.90, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -30.53%, a ROC of -99.51% and a ROE of -73.85%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Galecto Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Galecto Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Galecto Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Galecto Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Galecto Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Galecto Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.01, ATR14 : 0.59, CCI20 : -33.63, Chaikin Money Flow : -0.26, MACD : -1.66, Money Flow Index : 46.69, ROC : -0.67, RSI : 36.15, STOCH (14,3) : 39.58, STOCH RSI : 1.00, UO : 36.04, Williams %R : -60.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Galecto Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis & impact a broad range of fibrotic & related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

CEO: Hans T. Schambye

Telephone: +45 70705210

Address: Ole Maaloes Vej 3, Copenhagen DK-2200, , DK

Number of employees: 20

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

40%60%

Bearish Bullish

60%40%

Bearish Bullish

50%50%

News

Stocktwits